Dabrafenib mesylate capsules

Dabrafenib is an anti-tumor drug containing dabrafenib mesylate, and its excipients are microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, and hydroxypropyl methylcellulose capsule shell. This product is mainly used in the clinic to treat BRAFV600 mutation-positive unresectable or metastatic melanoma, and BRAFV600 mutation-positive unresectable or metastatic melanoma must be used in combination with trametinib. Its clinical indications include:
For non-small cell lung cancer: Before starting treatment with dabrafenib and trametinib, please confirm the presence of BRAFV600 mutation in the tumor specimen.
For BRAFV600 mutation-positive unresectable or metastatic melanoma.
For postoperative adjuvant treatment of BRAFV600 mutation-positive melanoma.